Explore our core VHH antibody discovery and yeast display screening service offerings — engineered for precision, speed, and scalability.
VHH antibodies — commonly known as nanobodies — are single-domain antibody fragments derived from the heavy-chain-only antibodies naturally found in camelids such as alpacas, llamas, and camels. With a molecular weight of only ~15 kDa, VHH domains are the smallest functional antibody fragments known, yet they retain full antigen-binding capability with exceptional affinity and specificity.
Yeast display screening is one of the most powerful platforms for VHH antibody discovery. In this system, VHH libraries are expressed on the surface of Saccharomyces cerevisiae (baker's yeast) cells as fusion proteins, allowing high-throughput screening using fluorescence-activated cell sorting (FACS). This eukaryotic expression environment ensures proper protein folding, post-translational modifications, and quality control — significantly improving the success rate of identifying functional, high-affinity VHH binders.
Unlike phage display, yeast display allows direct quantitative screening by FACS, enabling simultaneous assessment of both affinity and expression level. Library sizes of 108–109 variants can be screened in a single round, dramatically reducing discovery timelines.
Our streamlined, end-to-end workflow integrates animal immunization, library construction, yeast display, FACS screening, and hit validation into a seamless discovery pipeline.
Alpaca/llama immunization with target antigen to generate robust immune VHH repertoires.
RNA extraction, VHH gene amplification, and cloning into yeast display vectors (108+ diversity).
VHH-Aga2p fusion expression on yeast cell surface with quality verification by flow cytometry.
Multi-round fluorescent antigen labeling and FACS sorting to isolate high-affinity binders.
ELISA, SPR/BLI affinity measurement, sequencing, and functional characterization of lead VHHs.
At ~15 kDa, VHH nanobodies penetrate dense tumor microenvironments, cross the blood-brain barrier, and access cryptic epitopes inaccessible to conventional antibodies — opening entirely new therapeutic windows.
VHH domains are highly thermostable, resistant to harsh pH conditions, and can be expressed at high yields in microbial systems — drastically reducing biomanufacturing costs compared to full-length IgG antibodies.
Yeast display combined with FACS enables simultaneous screening of millions of variants with real-time affinity ranking — dramatically outperforming traditional panning-based methods in hit quality and diversity.
The global nanobody market is undergoing explosive growth, driven by breakthroughs in oncology, neurology, and industrial biotechnology. Yeast display has become the platform of choice for leading biopharmaceutical companies and CROs alike.
The global nanobody/VHH antibody market is projected to surpass USD 4.5 billion by 2030, growing at a CAGR exceeding 22%. Yeast display screening services represent one of the fastest-growing segments within antibody discovery CRO markets, as pharmaceutical companies increasingly outsource early-stage discovery to specialized platforms.
Beyond therapeutics, VHH nanobodies discovered via yeast display are being deployed in industrial enzyme stabilization, food safety rapid testing, environmental contaminant detection, and point-of-care diagnostic devices — where their extreme stability and small size offer unmatched advantages over conventional antibodies.
Following the approval of caplacizumab (Cablivi) — the world's first nanobody drug — the pipeline has expanded dramatically. Over 50 VHH-based therapeutics are currently in clinical trials globally, with yeast display screening credited for identifying many lead candidates in record time.
Leading CROs are integrating machine learning models with yeast display datasets to predict VHH affinity, stability, and developability prior to wet-lab screening — reducing experimental iterations by up to 60% and enabling in silico pre-selection of library variants for FACS screening.
Yeast display-derived VHHs are increasingly being reformatted into bispecific nanobodies, VHH-Fc fusions, nanobody-drug conjugates (NDCs), and CAR-T cell constructs. Their modular architecture makes them ideal building blocks for next-generation biologic medicines with enhanced tumor targeting and reduced off-target effects.
The outsourcing of VHH discovery to specialized CROs has grown over 35% year-on-year since 2021. Companies in North America, Europe, and Asia-Pacific are all investing heavily in yeast display infrastructure, with China emerging as a major hub for cost-competitive, high-quality VHH discovery services.
From oncology to agriculture, VHH nanobodies discovered through yeast display screening are reshaping how biologics are developed and deployed across industries.
VHH nanobodies identified through yeast display FACS screening are being engineered as checkpoint inhibitors, bispecific T-cell engagers (BiTEs), and tumor-penetrating delivery vehicles. Their ability to access cryptic epitopes on EGFR, HER2, PD-L1, and VEGFR that are inaccessible to conventional antibodies makes them transformative in solid tumor therapy.
Yeast display enables direct screening against native membrane-bound tumor antigens expressed on intact cells — a critical advantage for GPCR and membrane protein targets that lose conformation when purified.
Learn More →
One of the most exciting frontiers for yeast display-derived VHHs is central nervous system drug delivery. Nanobodies' small size (~2.5 nm diameter) enables passive and active transcytosis across the blood-brain barrier — a barrier that blocks >98% of conventional biologics. VHHs against amyloid-beta, tau, and alpha-synuclein are being developed as both diagnostics and therapeutics for Alzheimer's and Parkinson's disease.
Yeast display screening allows identification of VHHs with simultaneous BBB-crossing capability and target engagement — a dual-function screening paradigm not achievable with phage display alone.
Learn More →
VHH nanobodies are ideal for lateral flow assay (LFA) development, electrochemical biosensors, and surface plasmon resonance (SPR)-based detection platforms. Their extreme thermal stability (withstanding >70°C) and tolerance to organic solvents make them indispensable for food safety testing, environmental monitoring, and industrial process control.
Yeast display screening has been used to develop VHHs against pesticide residues, heavy metals, mycotoxins, and viral pathogens — enabling point-of-care detection at sensitivities previously achievable only in centralized laboratories.
Learn More →Years of manufacturing excellence and refined discovery platforms deliver superior results for our global partners.
Our platform utilizes phage and yeast display technology to develop different forms of antibodies: VHH single domain antibodies, Fab antibodies, and scFv antibodies, resulting in high affinity and high specificity antibodies.
READ MORE →
VHH Antibody Discovery Service
View Details
Fab Antibody Discovery Service
View Details
ScFv Antibody Discovery Service
View Details
Phage Display System
View Details
Phage Library Construction Service
View Details
The aptamer platform provided by Alpha Lifetech includes two categories: aptamer synthesis platform, which mainly involves SELEX aptamer library synthesis service and aptamer development service, and aptamer screening platform including screening services based on SELEX technology for proteins, peptides, cells, small molecules, and other target molecules, as well as aptamer optimization and identification analysis services.
READ MORE →
Aptamer Synthesis Platform
View Details
Aptamer Screening Platform
View Details
Aptamer Optimization Service
View Details
Aptamer Analysis Service
View Details
Aptamer Research Service
View Details
Our monoclonal antibody development services include three technologies: phage display technology, single-B cell technology, and hybridoma cell technology, which produce monoclonal antibodies for different species.
READ MORE →
Single B Cell Sorting Platform
View Details
Hybridoma Technology Platform
View Details
Phage Display Technology Platform
View Details
Mouse mAb Development Service
View Details
Rabbit mAb Development Service
View Details
We also provide a series of technical services related to antibody engineering, stable cell line construction, yeast display, protein interaction analysis, etc., laying the foundation for antibody development.
READ MORE →
Stable Cell Line Construction Service
View Details
Animal Immunization Platform
View Details
Protein Interaction Service
View Details
Yeast Display Library Construction Service
View Details
Yeast Display Library Screening Service
View DetailsThrough tailored products, adaptable service and packaging choices, and unwavering support, Alpha Lifetech Inc. guarantees that researchers have access to the most fitting and efficient tools tailored to their research endeavors.
What our global partners say about Alpha Lifetech's VHH nanobody discovery and yeast display screening services.
Exceptional Nanobody discovery capabilities from Alpha Lifetech. Their team's dedication to customer satisfaction and scientific excellence is evident in every interaction. Grateful for their partnership and looking forward to future collaborations!
— Riley HarperQuality products! Our experience with Alpha Lifetech has been nothing short of outstanding. Their yeast display screening platform delivered high-affinity VHH leads in record time.
— Stella GrantReliable, responsive, and results-driven — Alpha Lifetech. Simply put, they deliver. Their dedication to customer satisfaction and quality service is unmatched, and we're grateful to have them as a trusted partner.
— Olivia WestSimply put, Alpha Lifetech delivers. Their dedication to customer satisfaction and quality service is unmatched, and we're grateful to have them as a trusted partner in our VHH drug discovery programs.
— Ava MitchellExplore our extensive catalog of biosimilar and isotype control antibodies supporting VHH discovery and yeast display screening research.
